First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers
Identifieur interne : 000D93 ( Istex/Corpus ); précédent : 000D92; suivant : 000D94First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers
Auteurs : Françoise Muller ; Clarisse Benattar ; François Audibert ; Nathalie Roussel ; Sophie Dreux ; Howard CuckleSource :
- Prenatal Diagnosis [ 0197-3851 ] ; 2003-10.
English descriptors
- KwdEn :
Abstract
In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester.
Url:
DOI: 10.1002/pd.700
Links to Exploration step
ISTEX:AE8AFC57AA98C36419A7082532751A29D36EB61FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title><author><name sortKey="Muller, Francoise" sort="Muller, Francoise" uniqKey="Muller F" first="Françoise" last="Muller">Françoise Muller</name><affiliation><mods:affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Benattar, Clarisse" sort="Benattar, Clarisse" uniqKey="Benattar C" first="Clarisse" last="Benattar">Clarisse Benattar</name><affiliation><mods:affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</mods:affiliation></affiliation></author><author><name sortKey="Audibert, Francois" sort="Audibert, Francois" uniqKey="Audibert F" first="François" last="Audibert">François Audibert</name><affiliation><mods:affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</mods:affiliation></affiliation></author><author><name sortKey="Roussel, Nathalie" sort="Roussel, Nathalie" uniqKey="Roussel N" first="Nathalie" last="Roussel">Nathalie Roussel</name><affiliation><mods:affiliation>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</mods:affiliation></affiliation></author><author><name sortKey="Dreux, Sophie" sort="Dreux, Sophie" uniqKey="Dreux S" first="Sophie" last="Dreux">Sophie Dreux</name><affiliation><mods:affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Cuckle, Howard" sort="Cuckle, Howard" uniqKey="Cuckle H" first="Howard" last="Cuckle">Howard Cuckle</name><affiliation><mods:affiliation>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AE8AFC57AA98C36419A7082532751A29D36EB61F</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/pd.700</idno><idno type="url">https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000D93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title><author><name sortKey="Muller, Francoise" sort="Muller, Francoise" uniqKey="Muller F" first="Françoise" last="Muller">Françoise Muller</name><affiliation><mods:affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Benattar, Clarisse" sort="Benattar, Clarisse" uniqKey="Benattar C" first="Clarisse" last="Benattar">Clarisse Benattar</name><affiliation><mods:affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</mods:affiliation></affiliation></author><author><name sortKey="Audibert, Francois" sort="Audibert, Francois" uniqKey="Audibert F" first="François" last="Audibert">François Audibert</name><affiliation><mods:affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</mods:affiliation></affiliation></author><author><name sortKey="Roussel, Nathalie" sort="Roussel, Nathalie" uniqKey="Roussel N" first="Nathalie" last="Roussel">Nathalie Roussel</name><affiliation><mods:affiliation>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</mods:affiliation></affiliation></author><author><name sortKey="Dreux, Sophie" sort="Dreux, Sophie" uniqKey="Dreux S" first="Sophie" last="Dreux">Sophie Dreux</name><affiliation><mods:affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</mods:affiliation></affiliation></author><author><name sortKey="Cuckle, Howard" sort="Cuckle, Howard" uniqKey="Cuckle H" first="Howard" last="Cuckle">Howard Cuckle</name><affiliation><mods:affiliation>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Prenatal Diagnosis</title><title level="j" type="sub">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title level="j" type="abbrev">Prenat. Diagn.</title><idno type="ISSN">0197-3851</idno><idno type="eISSN">1097-0223</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2003-10">2003-10</date><biblScope unit="volume">23</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="833">833</biblScope><biblScope unit="page" to="836">836</biblScope></imprint><idno type="ISSN">0197-3851</idno></series><idno type="istex">AE8AFC57AA98C36419A7082532751A29D36EB61F</idno><idno type="DOI">10.1002/pd.700</idno><idno type="ArticleID">PD700</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0197-3851</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>aneuploidy</term><term>first trimester</term><term>nuchal translucency</term><term>screening</term><term>trisomy 21</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Françoise Muller</name><affiliations><json:string>Biochimie, Hôpital Ambroise Paré, Boulogne, France</json:string></affiliations></json:item><json:item><name>Clarisse Benattar</name><affiliations><json:string>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</json:string></affiliations></json:item><json:item><name>François Audibert</name><affiliations><json:string>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</json:string></affiliations></json:item><json:item><name>Nathalie Roussel</name><affiliations><json:string>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</json:string></affiliations></json:item><json:item><name>Sophie Dreux</name><affiliations><json:string>Biochimie, Hôpital Ambroise Paré, Boulogne, France</json:string></affiliations></json:item><json:item><name>Howard Cuckle</name><affiliations><json:string>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>trisomy 21</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>aneuploidy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>nuchal translucency</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>first trimester</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>screening</value></json:item></subject><articleId><json:string>PD700</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>3.395</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>339</abstractCharCount><pdfWordCount>2807</pdfWordCount><pdfCharCount>17421</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>49</abstractWordCount></qualityIndicators><title>First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title><genre><json:string>article</json:string></genre><host><volume>23</volume><publisherId><json:string>PD</json:string></publisherId><pages><total>4</total><last>836</last><first>833</first></pages><issn><json:string>0197-3851</json:string></issn><issue>10</issue><subject><json:item><value>Original Paper</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1097-0223</json:string></eissn><title>Prenatal Diagnosis</title><doi><json:string>10.1002/(ISSN)1097-0223</json:string></doi></host><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1002/pd.700</json:string></doi><id>AE8AFC57AA98C36419A7082532751A29D36EB61F</id><score>0.18665133</score><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><p>Copyright © 2003 John Wiley & Sons, Ltd.</p></availability><date>2003</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title><author xml:id="author-1"><persName><forename type="first">Françoise</forename><surname>Muller</surname></persName><note type="correspondence"><p>Correspondence: Biochimie, Hôpital Ambroise Paré, 92104, Boulogne, France.</p></note><affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation></author><author xml:id="author-2"><persName><forename type="first">Clarisse</forename><surname>Benattar</surname></persName><affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</affiliation></author><author xml:id="author-3"><persName><forename type="first">François</forename><surname>Audibert</surname></persName><affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</affiliation></author><author xml:id="author-4"><persName><forename type="first">Nathalie</forename><surname>Roussel</surname></persName><affiliation>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</affiliation></author><author xml:id="author-5"><persName><forename type="first">Sophie</forename><surname>Dreux</surname></persName><affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation></author><author xml:id="author-6"><persName><forename type="first">Howard</forename><surname>Cuckle</surname></persName><affiliation>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</affiliation></author></analytic><monogr><title level="j">Prenatal Diagnosis</title><title level="j" type="sub">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title level="j" type="abbrev">Prenat. Diagn.</title><idno type="pISSN">0197-3851</idno><idno type="eISSN">1097-0223</idno><idno type="DOI">10.1002/(ISSN)1097-0223</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2003-10"></date><biblScope unit="volume">23</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="833">833</biblScope><biblScope unit="page" to="836">836</biblScope></imprint></monogr><idno type="istex">AE8AFC57AA98C36419A7082532751A29D36EB61F</idno><idno type="DOI">10.1002/pd.700</idno><idno type="ArticleID">PD700</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester.</p></abstract><abstract><p>Between January 1998 and June 2001, all women who presented for their prenatal care at 12 participating maternity units were, regardless of age, invited to provide a blood sample and to attend for an NT scan at 11 to 13 weeks. The results were used to derive Gaussian distribution parameters. Detection and false‐positive rates were computed in two ways: statistical modelling and directly. The cut‐off risk was 1 in 250 at term.</p></abstract><abstract><p>A total of 5694 women with singleton pregnancies were screened including 26 with Down syndrome and 24 with other aneuploidies. The model‐predicted detection and false‐positive rates for combined ultrasound and serum screening were 81 and 4.5% compared to 64 and 6.0% for ultrasound alone. The directly observed rates were 73 and 4.7%, compared to 62 and 5.0% respectively.</p></abstract><abstract><p>In France, first‐trimester screening with nuchal translucency and maternal serum markers is likely to achieve a high screening efficiency. This has important implications for the national screening policy. Copyright © 2003 John Wiley & Sons, Ltd.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>trisomy 21</term></item><item><term>aneuploidy</term></item><item><term>nuchal translucency</term></item><item><term>first trimester</term></item><item><term>screening</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Original Paper</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-01-30">Received</change><change when="2003-07-06">Registration</change><change when="2003-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1097-0223</doi><issn type="print">0197-3851</issn><issn type="electronic">1097-0223</issn><idGroup><id type="product" value="PD"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PRENATAL DIAGNOSIS">Prenatal Diagnosis</title><title type="subtitle">Published in Affiliation With the International Society for Prenatal Diagnosis</title><title type="short">Prenat. Diagn.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/pd.v23:10</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2003-10">October 2003</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="12" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pd.700</doi><idGroup><id type="unit" value="PD700"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Original Paper</title><title type="tocHeading1">Original Papers</title></titleGroup><copyright ownership="publisher">Copyright © 2003 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="manuscriptReceived" date="2003-01-30"></event><event type="manuscriptRevised" date="2003-07-02"></event><event type="manuscriptAccepted" date="2003-07-06"></event><event type="firstOnline" date="2003-09-05"></event><event type="publishedOnlineFinalForm" date="2003-09-05"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">833</numbering><numbering type="pageLast">836</numbering></numberingGroup><correspondenceTo>Biochimie, Hôpital Ambroise Paré, 92104, Boulogne, France.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PD.PD700.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="17"></count></countGroup><titleGroup><title type="main" xml:lang="en">First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title><title type="short" xml:lang="en">FIRST‐TRIMESTER SCREENING FOR DOWN SYNDROME IN FRANCE</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Françoise</givenNames><familyName>Muller</familyName></personName><contactDetails><email normalForm="francoise.muller@apr.ap-hop-paris.fr">francoise.muller@apr.ap‐hop‐paris.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Clarisse</givenNames><familyName>Benattar</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>François</givenNames><familyName>Audibert</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Nathalie</givenNames><familyName>Roussel</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Sophie</givenNames><familyName>Dreux</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Howard</givenNames><familyName>Cuckle</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="GB" type="organization"><unparsedAffiliation>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">trisomy 21</keyword><keyword xml:id="kwd2">aneuploidy</keyword><keyword xml:id="kwd3">nuchal translucency</keyword><keyword xml:id="kwd4">first trimester</keyword><keyword xml:id="kwd5">screening</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background</title><p>In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester.</p></section><section xml:id="abs1-2"><title type="main">Methods</title><p>Between January 1998 and June 2001, all women who presented for their prenatal care at 12 participating maternity units were, regardless of age, invited to provide a blood sample and to attend for an NT scan at 11 to 13 weeks. The results were used to derive Gaussian distribution parameters. Detection and false‐positive rates were computed in two ways: statistical modelling and directly. The cut‐off risk was 1 in 250 at term.</p></section><section xml:id="abs1-3"><title type="main">Results</title><p>A total of 5694 women with singleton pregnancies were screened including 26 with Down syndrome and 24 with other aneuploidies. The model‐predicted detection and false‐positive rates for combined ultrasound and serum screening were 81 and 4.5% compared to 64 and 6.0% for ultrasound alone. The directly observed rates were 73 and 4.7%, compared to 62 and 5.0% respectively.</p></section><section xml:id="abs1-4"><title type="main">Conclusion</title><p>In France, first‐trimester screening with nuchal translucency and maternal serum markers is likely to achieve a high screening efficiency. This has important implications for the national screening policy. Copyright © 2003 John Wiley & Sons, Ltd.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>FIRST‐TRIMESTER SCREENING FOR DOWN SYNDROME IN FRANCE</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers</title></titleInfo><name type="personal"><namePart type="given">Françoise</namePart><namePart type="family">Muller</namePart><affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation><description>Correspondence: Biochimie, Hôpital Ambroise Paré, 92104, Boulogne, France.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Clarisse</namePart><namePart type="family">Benattar</namePart><affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Audibert</namePart><affiliation>Biochimie et Obstétrique, Hôpital Antoine Béclère, Clamart, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nathalie</namePart><namePart type="family">Roussel</namePart><affiliation>Biologie Endocrinienne et Osseuse, Hôpital Sud, Amiens, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sophie</namePart><namePart type="family">Dreux</namePart><affiliation>Biochimie, Hôpital Ambroise Paré, Boulogne, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Howard</namePart><namePart type="family">Cuckle</namePart><affiliation>Reproductive Epidemiology, School of Medicine, University of Leeds, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2003-10</dateIssued><dateCaptured encoding="w3cdtf">2003-01-30</dateCaptured><dateValid encoding="w3cdtf">2003-07-06</dateValid><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">17</extent></physicalDescription><abstract>In France, there is a strictly regulated National Screening Programme for Down syndrome, based on second‐trimester maternal serum markers. A prospective study of nuchal translucency together with retrospective evaluation of maternal serum markers was carried out to inform decisions on whether to move the programme to the first trimester.</abstract><abstract>Between January 1998 and June 2001, all women who presented for their prenatal care at 12 participating maternity units were, regardless of age, invited to provide a blood sample and to attend for an NT scan at 11 to 13 weeks. The results were used to derive Gaussian distribution parameters. Detection and false‐positive rates were computed in two ways: statistical modelling and directly. The cut‐off risk was 1 in 250 at term.</abstract><abstract>A total of 5694 women with singleton pregnancies were screened including 26 with Down syndrome and 24 with other aneuploidies. The model‐predicted detection and false‐positive rates for combined ultrasound and serum screening were 81 and 4.5% compared to 64 and 6.0% for ultrasound alone. The directly observed rates were 73 and 4.7%, compared to 62 and 5.0% respectively.</abstract><abstract>In France, first‐trimester screening with nuchal translucency and maternal serum markers is likely to achieve a high screening efficiency. This has important implications for the national screening policy. Copyright © 2003 John Wiley & Sons, Ltd.</abstract><subject lang="en"><genre>keywords</genre><topic>trisomy 21</topic><topic>aneuploidy</topic><topic>nuchal translucency</topic><topic>first trimester</topic><topic>screening</topic></subject><relatedItem type="host"><titleInfo><title>Prenatal Diagnosis</title><subTitle>Published in Affiliation With the International Society for Prenatal Diagnosis</subTitle></titleInfo><titleInfo type="abbreviated"><title>Prenat. Diagn.</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Original Paper</topic></subject><identifier type="ISSN">0197-3851</identifier><identifier type="eISSN">1097-0223</identifier><identifier type="DOI">10.1002/(ISSN)1097-0223</identifier><identifier type="PublisherID">PD</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>833</start><end>836</end><total>4</total></extent></part></relatedItem><identifier type="istex">AE8AFC57AA98C36419A7082532751A29D36EB61F</identifier><identifier type="DOI">10.1002/pd.700</identifier><identifier type="ArticleID">PD700</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2003 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Ltd.</recordOrigin></recordInfo></mods></metadata><enrichments><json:item><type>multicat</type><uri>https://api.istex.fr/document/AE8AFC57AA98C36419A7082532751A29D36EB61F/enrichments/multicat</uri></json:item></enrichments><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000D93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:AE8AFC57AA98C36419A7082532751A29D36EB61F
|texte= First‐trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers
}}
| This area was generated with Dilib version V0.6.25. |  |